[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sudden-hearing-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sudden-hearing-loss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,71,95,118,151,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634518","phase-2-trans-round-window-membrane-intracochlear-steroid-100634518",false,"NCT07540728","Trans-round Window Membrane Intracochlear Steroid","Efficacy and Safety of Trans-Round Window Membrane Intracochlear Steroid Delivery in Patients With Complete Sudden Sensorineural Hearing Loss","Inclusion Criteria:\n\n* Age between 12 and 75 years Unilateral idiopathic sudden sensorineural hearing loss diagnosed by Pure tone test, CT and MRI Symptoms of sudden deafness occur within ≥ 7 days and, after conventional treatment, the average thresholds at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz are ≥ 80 dBHL\n\nExclusion Criteria:\n\n* Bilateral sudden sensorineural hearing loss Hearing loss with known causes (e.g., Meniere's disease, retrocochlear pathology, history of otologic surgery, perilymphatic fistula, barotrauma) History in the past 6 months of ototoxic treatment such as chemotherapy, use of loop diuretics, high dose aspirin, etc.\n\nHistory of sudden sensorineural hearing loss within the past 2 years History of ischemic diseases (cerebral infarction, myocardial infarction, peripheral arterial obstructive disease) Neuropsychiatric disorders (epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis) Severe hepatic or renal insufficiency","ALL","12 Years","75 Years",{"count":20,"type":21},108,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Safety and efficacy of intracochlear injection of glucocorticoid through the round window membrane in patients with profound or complete sudden sensorineural hearing loss",[27],"Sudden Hearing Loss",[29,30,31],"intracochlear injection","glucocorticoid","round window membrane","NOT_YET_RECRUITING","2026-04-13",{"date":35,"type":36},"2026-04-20","ACTUAL",{"date":35,"type":21},{"date":39,"type":21},"2028-05-01",{"name":41,"class":42},"Eye & ENT Hospital of Fudan University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100631821","yiyuancong-for-the-treatment-of-sudden-sensorineural-hearing-loss-100631821","NCT07505667","Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss","Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss: A Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Unilateral sudden sensorineural hearing loss (SSNHL) occurring within 72 hours, with a hearing threshold decrease of 20 dB at at least two consecutive frequencies.\n2. Enrollment must be completed within 14 days of the onset of SSNHL.\n3. Males or females aged 18 to 60 years.\n4. Ability to understand the study protocol and comply with regular follow-up visits.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation (breastfeeding).\n2. History of chronic ear disease, prior ear surgery, autoimmune hearing loss, or a confirmed diagnosis of Meniere's disease.\n3. Receipt of corticosteroid therapy for any reason within the previous 30 days.\n4. Presence of autoimmune diseases or chronic inflammatory diseases.\n5. Severe hepatic or renal impairment.\n6. Any other condition that, in the opinion of the investigator, renders the participant unsuitable for inclusion.","18 Years","60 Years",{"count":54,"type":21},128,[56],"NA","This project aims to evaluate the clinical efficacy of Yiyuancong, an independently developed traditional Chinese medicine (TCM) formula based on the homology of medicine and food, in participants with sudden sensorineural hearing loss (SSNHL) and to elucidate its potential underlying mechanisms. This study is designed as a multicenter, randomized controlled trial (RCT), utilizing dynamic randomization for participant allocation. Due to the requirement for the experimental group to continuously administer the TCM preparation for 1-2 months, this study is conducted as an open-label (non-blinded) trial. All participants will undergo audiological evaluations at baseline, day 7 of treatment, and upon completion of the first and second treatment courses.\n\nBased on previous research regarding integrated traditional Chinese and Western medicine for SSNHL, the estimated effect size (ES) for the improvement of pure-tone thresholds compared with Western medicine alone ranges from 0.5 to 0.8. Assuming an effect size of 0.5 for the difference in pure-tone audiometry (PTA) improvement between the experimental and control groups, with a significance level (α) of 0.05 (one-tailed) and a statistical power (1-β) of 0.8, the required sample size calculated via G\\*Power software is 51 per group. Accounting for a 20% dropout rate, the investigators plan to enroll 64 participants per group (total N = 128).",[27,59],"Sensorineural Hearing Loss","RECRUITING","2026-03-26",{"date":63,"type":36},"2026-04-01",{"date":65,"type":36},"2025-11-15",{"date":67,"type":21},"2027-11-15",{"name":69,"class":42},"Guangdong Provincial People's Hospital",5,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":70},"100624059","phase-1-study-on-the-safety-and-efficacy-of-intratympanic-injection-of-small-extracellular-vesicles-derived-from-mesenchymal-stem-cells-in-severe-and-profound-sudden-sensorineural-hearing-loss-100624059","NCT07404709","Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","Clinical Phase I and IIa Trials of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","Inclusion Criteria:\n\n1. Sudden unilateral hearing loss that occurs within 72 hours, with a decrease of at least 30 decibels in at least 3 frequency ranges compared to the healthy ear, and an average pure tone threshold of ≥ 65 decibels.\n2. Enrollment must be completed within 7 days after the onset of sudden deafness.\n3. Men or women aged 18 to 65\n4. Not treated in any other hospital and not taking any treatment medication on one's own\n5. Be able to understand the trial protocol and undergo regular follow-up visits and check-ups\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. With a history of chronic ear diseases, ear surgery, autoimmune hearing loss or a confirmed diagnosis of Meniere's syndrome in the past\n3. Having received steroid treatment for any reason within the past 30 days\n4. There are autoimmune diseases or chronic inflammatory diseases.\n5. Severe damage to liver and kidney functions\n6. Patients with a previous history of cerebral hemorrhage or those currently taking anticoagulant medications\n7. Other cases in which the researchers judged the candidates to be unsuitable for inclusion","65 Years",{"count":80,"type":21},9,[82,24],"PHASE1","The goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss. It will also learn about the safety of small extracellular vesicles. The main questions it aims to answer are:\n\n1. Does small extracellular vesicles combined with traditional drug treatment improve hearing even better in severe and above sudden deafness participants?\n2. What medical problems do participants have with intratympanic injection of small extracellular vesicles? Researchers will compare small extracellular vesicles to dexamethasone to see if small extracellular vesicles work to treat severe and above sudden sensorineural hearing loss.\n\nIn clinical Phase I trial, the investigators will complete the safety check and dose exploration.\n\nParticipants will:\n\n1. Receive traditional drug treatment in accordance with the \"Guidelines for the Diagnosis and Treatment of Sudden Deafness (2015)\n2. Receive small extracellular vesicles or a placebo tympanic injection additionally\n3. Visit the clinic once every 2 weeks for checkups and tests\n4. Receive tympanic injections of small extracellular vesicles ranging from low concentration to high concentration\n5. Be evaluated for any adverse reactions In clinical Phase II trial, participants were randomly divided into a control group and an experimental group.\n\n   Participants will:\n6. Received intratympanic injections of small extracellular vesicles 3 times together with traditional drug treatment in experimental group\n7. Received intratympanic injections of 5mg dexamethasone 3 times together with traditional drug treatment in control group, also for a total of 3 times Visit the clinic once 7 days , 1month and 3 months after treatment for checkups and tests of pure tone audiometry, speech audiometry, tinnitus disability scale and visual analogue scale assessment",[27,85],"Extracellular Vesicles","2026-03-21",{"date":88,"type":36},"2026-03-25",{"date":90,"type":21},"2026-02-28",{"date":92,"type":21},"2028-12-31",{"name":94,"class":42},"The Affiliated Hospital of Qingdao University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":43},"100611046","effectiveness-of-integrative-medical-treatment-in-sudden-hearing-loss-100611046","NCT07235488","Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss","Inclusion Criteria:\n\n* Age ≥18 years, both male and female.\n* Meeting the diagnostic criteria for sudden sensorineural hearing loss (SSNHL), defined as hearing loss of \\>30 dB affecting at least three consecutive frequencies within 3 days.\n* Newly onset of hearing loss within 2 week.\n* Fully understanding the purpose and procedures of the study and providing signed informed consent.\n\nExclusion Criteria:\n\n* Central nervous system lesions such as vestibular schwannoma or traumatic brain injury.\n* Middle ear or retrocochlear pathology.\n* History of otologic surgery.\n* Hemorrhagic disorders or coagulation abnormalities.\n* Inability to cooperate with examinations due to dementia or psychiatric illness.\n* Previous treatment for SSNHL on the same affected side within the past 6 months.",{"count":102,"type":21},64,[56],"Sudden hearing loss is an emergency in otolaryngology that requires diagnosis and treatment as soon as possible. The golden treatment period is two weeks since the onset of the disease. However, modern medicine is still unable to fully understand the causes of the disease and in lack of corresponding effective treatments. Current therapies also have their own limitations and side effects. To find an effective and safe treatment, integrating with modern medicine and providing inpatient and outpatient medical care, is an important issue in clinical care. Traditional Chinese medicine has been clinically utilized for a long time with accumulated empirical experience and evidence for its efficacy. It can be used as an alternative therapeutic option for sudden hearing loss.\n\nBeing with a long period of clinical experience and evidence-based curative effect, acupuncture could be applied as an adjunctive treatment for the sudden hearing loss. Currently, this patient-centered, pragmatic clinical trial compares the effectiveness of using west medicine、combination of west medicine and traditional Chinese medicine. The aim of this study is to explore acceptable and beneficial strategy to reduce the clinical symptoms, to improve quality of life, and decrease medical expenses.",[27],[107,108],"sudden hearing loss","acupuncture","2025-11-17",{"date":111,"type":36},"2025-11-19",{"date":113,"type":36},"2024-07-08",{"date":115,"type":21},"2026-06-20",{"name":117,"class":42},"China Medical University Hospital",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":129,"studyType":130,"phases":4,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":43},"100475748","sudden-sensorineural-hearing-loss-in-wonju-severance-christian-hospital-100475748","NCT05474963","Sudden Sensorineural Hearing Loss in Wonju Severance Christian Hospital","Prospective Cohort Study of Sudden Sensorineural Hearing Loss in Wonju Severance Christian Hospital","Inclusion Criteria:\n\n* Adult patients over 20 years of age\n* A patient who visited Wonju Severance Christian Hospital, Department of Otolaryngology and was diagnosed with sudden hearing loss as it was confirmed that hearing loss of 30dBHL or more occurred within 3 days at three consecutive frequencies in a pure tone audiometry test.\n* Those who have fully explained the purpose and content of the study and voluntarily agreed to the written consent\n\nExclusion Criteria:\n\n* If the patients do not want to or do not fill out the consent form\n* If treatment is started for sudden hearing loss, but the possibility of other inner ear diseases including Meniere's disease is suspected due to repeated hearing loss, repeated recovery, dizziness, tinnitus, etc.\n* Other cases where it is judged difficult to carry out the clinical trial due to the judgment of the person in charge of the above clinical trial","20 Years","100 Years",{"count":128,"type":21},1000,"6 Months","OBSERVATIONAL","This study is to build a cohort of sudden sensorineural hearing loss (SSNHL) patients. When the patient visited the Department of otolaryngology clinic for hearing loss, we can diagnose the SSNHL following the result of pure tone audiometry and the history of the patient. The cohort is a system that tracks the hearing recovery status, timing, and degree of recovery of patients who received cocktail therapy with or without high-dose steroids, vasodilators, antiviral agents, and intratympanic steroid injections, satellite ganglion block, and hyperbaric oxygen therapy.",[133,27,134,135],"SSNHL(Sudden Sensory Neural Hearing Loss)","Hearing Loss, Idiopathic Sudden Sensorineural","Hearing Loss, Sudden",[137,138,139,140,141],"Hearing Loss","Hearing Loss, sudden","SSNHL","Sudden sensorineural hearing loss","sudden sensory neural hearing loss","2025-03-23",{"date":144,"type":36},"2025-03-26",{"date":146,"type":36},"2021-07-14",{"date":148,"type":21},"2035-12-31",{"name":150,"class":42},"Wonju Severance Christian Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100552010","phase-2-efficacy-and-safety-of-hydroxychloroquine-in-the-treatment-of-sudden-sensorineural-hearing-loss-100552010","NCT06467526","Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss","Inclusion Criteria:\n\n1. Unilateral idiopathic sudden sensorineural hearing loss ≥ 30 dB in at least 3 consecutive frequencies, compared to the contralateral ear, within 3 days\n2. Enrollment has to be accomplished within 14 days after SSNHL onset\n3. Male or female aged ≥ 18 to 70 years\n4. Ability to understand and follow the study protocol\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding female\n2. positive pregnancy test before receiving the study drug\n3. Due to a history of physical efforts suspected perilymph fistula or membrane rupture.\n4. Previously existing, known retrocochlear hearing loss\n5. Any history of any ear operation or chronic inflammatory disease of middle ear in the past one year\n6. History of blunt or penetrating ear trauma, head trauma, barotrauma, or acoustic trauma immediately preceding SSHL.\n7. History of Meniere's disease, autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops, and otosclerosis.\n8. History of chronic inflammatory diseases or autoimmune diseases\n9. Prior chemotherapy or treatment with immunosuppressant drugs\n10. Patients on renal dialysis\n11. Patients with history of retinopathy, or are using drugs that could induce retinopathy, such as Tamoxifen\n12. History of allergy to hydroxychloroquine\n13. Patients who are contraindicated with oral steroid treatment","70 Years",{"count":159,"type":21},80,[24],"Sudden sensorineural hearing loss (SSNHL) is diagnosed when there's a sudden drop in hearing of at least 30 decibels across three consecutive frequencies, emerging within up to 72 hours. In clinical settings, steroids are the predominant treatment for SSNHL. However, the outcomes for patients undergoing steroid therapy for SSNHL can differ substantially. Moreover, a systematic review of randomized clinical trials has found no conclusive evidence pinpointing an effective treatment for SSNHL. Hydroxychloroquine, a derivative of chloroquine, is a medication that has gained attention for its potential role in modulating the immune response. We aim to see if hydroxychloroquine could augment hearing recovery in SSNHL under steroid treatment and to evaluate the safety of hydroxychloroquine in the treatment of SSNHL patients. We plan to enroll 80 SSNHL patients who received oral steroid therapy and randomize them into an experimental group (hydroxychloroquine with prednisolone, 40 patients) and a control group (prednisolone, 40 patients). The primary endpoint will be the change in pure tone audiogram (PTA) in the affected ear from screening until 3 months. The secondary endpoints will be the change in word recognition score and the change in bilateral tinnitus severity after treatment. Any side effects will be recorded to ensure the safety of this clinical trial.",[27],"2024-06-16",{"date":165,"type":36},"2024-06-21",{"date":167,"type":21},"2024-07-01",{"date":169,"type":21},"2027-03-31",{"name":171,"class":42},"Chang Gung Memorial Hospital",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":157,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":43},"100377294","phase-4-the-effect-of-pap-on-isshl-comorbided-with-osa-100377294","NCT04192656","The Effect of PAP on ISSHL Comorbided With OSA","The Effect of Positive Airway Pressure on Idiopathic Sudden Sensorineural Hearing Loss Comorbided With Obstructive Sleep Apnea: A Clinical Randomized Controlled Study","Inclusion Criteria:\n\n1. aged \\>= 18 and \\\u003C= 70,\n2. diagnosed with OSA by full-night in-lab or home-stay PSG according to AASM 2012 criteria, and AHI \\> 15\u002Fh,\n3. diagnosed with ISSHL by AAO-HNS 2019 criteria,\n4. ISSHL onset within 1 week.\n\nExclusion Criteria:\n\n1. sudden hearing loss with certain causes,\n2. with severe comorbid diseases,\n3. pregnant or breast-feeding women,\n4. AHI \\\u003C= 15\u002Fh,\n5. hearing threshold recovered \\> 50% when included,\n6. previously regularly treated with PAP.",{"count":180,"type":21},102,[182],"PHASE4","This clinical randomized controlled study is to explore the effect of positive airway pressure(PAP) on patients in Beijing Tsinghua Changgung Hospital diagnosed with both idiopathic sudden sensorineural hearing loss comorbided(ISSHL) and obstructive sleep apnea(OSA) between Dec. 2019 to Dec. 2029.",[27,185],"Obstructive Sleep Apnea","2019-12-09",{"date":188,"type":36},"2019-12-10",{"date":190,"type":36},"2019-11-01",{"date":192,"type":21},"2029-12",{"name":194,"class":42},"Beijing Tsinghua Chang Gung Hospital"]